Company news

Xiamen Amoytop Biotech Co., Ltd. Class A (SSE:688278) news

Xiamen Amoytop Biotech Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (688278)"Xiamen Amoytop Biotech Co., Ltd."Announcement on Satisfaction…

Xiamen Amoytop Biotech Co., Ltd. Class A (SSE:688278) news

Press releases & updates

(688278)"Xiamen Amoytop Biotech Co., Ltd."Announcement on Satisfaction of Vesting Conditions for the Second Vesting Period of the Initial Grant and the First Vesting Period of the Reserved Grant under the 2024 Restricted Share Incentive Plan

(688278)"Xiamen Amoytop Biotech Co., Ltd."Announcement on Resolutions of the 25th Meeting of the 9th Board of Directors

(688278)"Xiamen Amoytop Biotech Co., Ltd."Announcement on Cancellation of Certain Granted but Unvested Restricted Shares under the 2024 Restricted Share Incentive Plan

(688278)"Xiamen Amoytop Biotech Co., Ltd."Announcement on Adjustment of the Grant Price under the 2024 Restricted Share Incentive Plan

(688278)"Xiamen Amoytop Biotech Co., Ltd."Announcement on Adding Implementation Locations for Certain Raised Funds Investment Projects Financed by Convertible Corporate Bonds

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Change of Board Secretary

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Resolutions of the 4th Extraordinary General Meeting in 2026

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Joint Investment with Related Parties and Related Party Transactions

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Use of Funds Raised from Convertible Corporate Bonds to Replace Self-raised Funds Previously Invested in Raised Funds Investment Projects and Paid Issuance Expenses

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Opening a Special Account for Raised Funds and Signing a Tripartite Supervision Agreement for Deposit of Raised Funds in Special Account

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Listing of Convertible Corporate Bonds Issued to Unspecified Investors

"Xiamen Amoytop Biotech Co., Ltd."Indicative Announcement on Results of Issuance of Convertible Corporate Bonds to Unspecified Investors

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Online Balloting Results for the Public Offering of Convertible Corporate Bonds to Unspecified Investors

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Online Subscription Success Rate and Priority Placement Results for the Public Offering of Convertible Bonds to Unspecified Investors

"Xiamen Amoytop Biotech Co., Ltd."Indicative Announcement on Issuance of Convertible Corporate Bonds to Unspecified Investors

"Xiamen Amoytop Biotech Co., Ltd."Announcement on the Online Roadshow for the Issuance of Convertible Corporate Bonds to Unspecified Investors

"Xiamen Amoytop Biotech Co., Ltd."Voluntary Disclosure Announcement on ACT201 Injection Obtaining Notice of Approval for Drug Clinical Trial

"Xiamen Amoytop Biotech Co., Ltd."Announcement on Progress in Repurchasing Shares

Announcement on Obtaining Registration Approval of Application for Issuing Convertible Corporate Bonds to Non-specific Objects from China Securities Regulatory Commission

Announcement on Repurchasing 2% Shares through Call Auction and Progress in Repurchasing Shares

Announcement on Voluntary Disclosure on the Acceptance Notification of Clinical Trial Application for ACT201 Injection

Announcement on Repurchasing 1% Shares through Call Auction and Progress in Repurchasing Shares

Announcement on Initially Repurchasing Shares through Call Auction and Progress in Repurchasing

Announcement on Adjusting Upper Limit of Share Repurchase Price after Implementation of Dividend Distribution for 2025

Announcement on Application for Issuance of Convertible Corporate Bonds to Non-specific Objects Approved by the Listing Review Committee of Shanghai Stock Exchange

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Without Sales Restrictions Concerning Share Repurchase

Announcement on Resolutions of the 20th Meeting of the 9th Board of Directors

Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026

Indicative Announcement on Reply to Review and Inquiry Letter of Issuance of Convertible Corporate Bonds by the Company to Non-specific Objects and Update of Application Documents such as Prospectus

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Report for Q1 2026

Announcement on Acceptance of Application for Issuing Convertible Corporate Bonds to Non-specific Objects by Shanghai Stock Exchange

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Initially Repurchasing the Company's Shares through Call Auction

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

Announcement on Convening the 2025 Annual Performance and Cash Dividend Briefing

Notice on Convening the 2025 Annual General Meeting

Announcement on Amending Articles of Association and Some Governance Systems

Announcement on the Chairman's Proposal to Repurchase Shares

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Voluntary Disclosure of a Wholly-owned Subsidiary Passing the High and New Technology Enterprise Certification

XIAMEN AMOYTOP BIOTECH CO., LTD. Announcement on Obtaining Notice of Approval for Drug Clinical Trial of ACT100 for Injection

Announcement on Voluntary Disclosure of Recognition of the Ninth Batch of National-level Manufacturing Single-Item Champion Enterprises

Indicative Announcement on Disclosure of Proposal for Issuing Convertible Corporate Bonds to Non-specific Objects

Announcement on Actual Controller Renewing the Concerted Action Agreement